What is the dosing of Ativan (lorazepam) for seizure management?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 23, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Lorazepam Dosing for Seizure Management

For seizure management, the recommended dose of lorazepam is 0.1 mg/kg intravenously (maximum 4 mg per dose), which may be repeated after 5-10 minutes if seizures persist. 1, 2

Adult Dosing

  • IV administration: 0.1 mg/kg (maximum 4 mg per dose), may be repeated after 10-15 minutes if seizures continue 1
  • For status epilepticus in adults (≥18 years): 4 mg given slowly (2 mg/min); may administer additional 4 mg dose after 10-15 minutes if seizures continue 1
  • Close monitoring of respiratory status is essential as respiratory depression is a significant risk 1

Pediatric Dosing

  • IV administration: 0.1 mg/kg (maximum 4 mg per dose) 2
  • For convulsive status epilepticus: 0.1 mg/kg IV (maximum 2 mg); may repeat after at least 1 minute (maximum 2 doses) 2
  • For non-convulsive status epilepticus: 0.05 mg/kg IV (maximum 1 mg); may repeat every 5 minutes (maximum 4 doses) 2
  • Maintenance dosing after resolution of status epilepticus: 0.05 mg/kg (maximum 1 mg) IV every 8 hours for 3 doses 2

Alternative Routes of Administration

  • Rectal administration: 0.5 mg/kg up to 20 mg (useful when IV access is unavailable, though absorption may be erratic) 2
  • Intranasal administration: 0.1 mg/kg (maximum 4 mg) has been shown to be non-inferior to IV administration in children 3
  • IM administration is generally not recommended for seizure management due to risk of tissue necrosis 2

Special Considerations

  • Equipment to maintain patent airway must be immediately available prior to administration 1
  • Monitor oxygen saturation and respiratory effort, as there is increased risk of apnea when combined with other sedative agents 2, 4
  • Flumazenil may be used to reverse life-threatening respiratory depression but will also counteract anticonvulsant effects and may precipitate seizures 2
  • Underdosing of lorazepam (less than 4 mg in adults >40 kg) has been associated with increased progression to refractory status epilepticus 5

Dosing in Special Populations

  • Elderly patients and those with hepatic disease: No dosage adjustments needed for acute administration 1
  • Patients with renal disease: No dosage adjustments needed for acute administration, but caution with frequent dosing over short periods 1

Common Pitfalls

  • Underdosing is common and associated with treatment failure; ensure appropriate weight-based dosing 5
  • Failure to have respiratory support immediately available 1
  • Delayed administration; lorazepam should be given promptly for seizure management 2
  • Not following lorazepam with a long-acting anticonvulsant (such as levetiracetam or phenytoin) when treating status epilepticus 2

Lorazepam has been shown to be as effective as diazepam-phenytoin combination in controlling pediatric convulsive status epilepticus, with the advantage of being a single drug 6. Even in neonates with refractory seizures, lorazepam at 0.05 mg/kg (up to 0.15 mg/kg total) has demonstrated efficacy 7.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Lorazepam Administration in Pediatric Patients

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Lorazepam versus diazepam-phenytoin combination in the treatment of convulsive status epilepticus in children: a randomized controlled trial.

European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society, 2010

Research

Lorazepam in the treatment of refractory neonatal seizures.

Journal of child neurology, 1991

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.